A Howe - Concepedia

Author

A Howe

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

A Howe, A Y Howe, A. Howe, A. Y. M. Howe, A.Y. Howe, A.Y.M. Howe, ANITA Y.M. Howe, Anita Howe, Anita Y M Howe, Anita Y. Howe

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Carmel Medical Center University of British Columbia The University of Texas Health Science Center at San Antonio Rambam Health Care Campus

About

A Howe is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in hepatitis, medicine, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	849
2	Epidemiology	3	3	87
3	Natural Sciences	2	2	67
4	Biochemistry	2	2	158
5	Public Health	1	1	21

A Howe

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Eric Lawitz, Edward Gane, Brian L. Pearlman, The Lancet Open-label Phase 2HepatologyHepatitis CViral HepatitisPrevious Null Response	2014	299
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent Xavier Forns, Stuart C. Gordon, Eli Zuckerman, Journal of Hepatology Viral HepatitisAntiviral TherapyHepatitisVirologyCombination Therapy	2015	140
Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors David R. McGivern, Takahiro Masaki, Sara E. Williford, Gastroenterology BiochemistryViral HepatitisMedicineAntiviral Drug DevelopmentAntiviral Therapy	2014	107
Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir Rong Liu, Stephanie Curry, Patricia McMonagle, Antimicrobial Agents and Chemotherapy	2015	76
A novel recombinant single‐chain hepatitis C virus ns3‐ns4a protein with improved helicase activity A Howe, Robert A. Chase, S. Shane Taremi, Protein Science Viral ReplicationHepatitis C VirusSynthetic VirologyMolecular BiologyViral Structural Protein	1999	51
O006 : C-swift: grazoprevir/elbasvir + sofosbuvir in cirrhotic and noncirrhotic, treatment-naive patients with hepatitis C virus genotype 1 infection, for durations of 4, 6 or 8 weeks and genotype 3 infection for durations of 8 or 12 weeks Fred Poordad, Eric Lawitz, Julio Gutiérrez, Journal of Hepatology Genotype 3Hepatic DisordersHepatologyHepatitis CViral Persistence	2015	45
The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis Michael P. Manns, John M. Vierling, Bruce R. Bacon, Gastroenterology Ribavirin Is EffectiveHepatologyHepatitis CViral HepatitisLiver Physiology	2014	39
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals A Howe, Chaturaka Rodrigo, Evan B. Cunningham, JHEP Reports	2022	39
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection A Howe, Stuart Black, Stephanie Curry, Clinical Infectious Diseases	2014	36
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras S. Süsser, Julia Dietz, Bernhard Schlevogt, Journal of Hepatology Viral PersistenceHepatologyHepatitis CViral HepatitisImmunology	2017	34

Page 1